Boehringer Ingelheim has appointed a new Chief Medical Officer in its current Global Head of Medicine in the Therapeutic Area Oncology, Dr Mehdi Shahidi.
Dr Shahidi, who will also take over the role of Corporate Senior Vice President Medicine, succeeds Dr Thor Voigt who will retire in April after 27 years with the business.
Dr Shahidi joined Boehringer Ingelheim in 2005 as a clinical development lead for oncology.
Over the following years, he assumed broader responsibilities in the Oncology TA in clinical development and medical affairs and in 2016 became Global Head of Medicine, Oncology.
Prior to joining the pharmaceutical industry, he had a successful clinical and research career.
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit, said: “We are fortunate to have many strong leaders in this area, and thank Dr Voigt for his excellent contributions.
“He will have a great successor in Dr Shahidi who takes over this important role as Chief Medical Officer with a well-deserved, excellent reputation inside and outside our company.”